MAZE Share Price Performance
US$14.25
-1.70 (-10.66%)
Price US$14.25
Share PriceUS$14.25
MAZE Community Narratives
There are no narratives available yet.
Recent MAZE News & Updates
No updates
Maze Therapeutics, Inc. Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- 0.071
- Gross Margin
- 100.00%
- Net Profit Margin
- 1.86%
- Debt/Equity Ratio
- 0%
Maze Therapeutics, Inc. Competitors
About MAZE
- Founded
- 2017
- Employees
- 125
- CEO
- WebsiteView website
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of renal, cardiovascular, related metabolic diseases, and obesity in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor of the solute transporter SLC6A19, which is in phase I clinical trial for the treatment of chronic kidney disease. The company also offers MZE001, a clinical program for the treatment of Pompe disease. Maze Therapeutics, Inc. was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.
U.S. Market Performance
- 7 Days: -1.2%
- 3 Months: 12.3%
- 1 Year: 21.3%
- Year to Date: 7.0%
In the last week, the market has fallen 1.2%, dragged down most by the Consumer Discretionary. In contrast to the last week, the market is actually up 21% over the past year. Looking forward, earnings are forecast to grow by 15% annually. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading